1. Variability in antifungal utilization among neonatal, pediatric, and adult inpatients in academic medical centers throughout the United States of America
- Author
-
Amy L. Pakyz, Jeremy S. Stultz, and Rose M. Kohinke
- Subjects
Adult ,Male ,0301 basic medicine ,Antifungal ,medicine.medical_specialty ,Antifungal Agents ,medicine.drug_class ,030106 microbiology ,Antimicrobial stewardship ,Pediatrics ,lcsh:Infectious and parasitic diseases ,Immunocompromised Host ,03 medical and health sciences ,0302 clinical medicine ,Medical microbiology ,Internal medicine ,medicine ,Humans ,Antifungal stewardship ,lcsh:RC109-216 ,030212 general & internal medicine ,Patient group ,Antibiotic use ,Child ,Antimicrobial trends ,Academic Medical Centers ,Inpatients ,Hematology ,business.industry ,Infant ,Neonates ,Hospitals ,United States ,Anti-Bacterial Agents ,Pediatric patient ,Infectious Diseases ,Tropical medicine ,Female ,business ,Invasive Fungal Infections ,Research Article - Abstract
Background Identification of factors associated with antifungal utilization in neonatal, pediatric, and adult patient groups is needed to guide antifungal stewardship initiatives in academic medical centers. Methods For this hospital-level analysis, we analyzed antifungal use in hospitals across the United States of America, excluding centers only providing care for hematology/oncology patients. Analysis of variance was used to compare antifungal use between patient groups. Three multivariable linear regression models were used to determine independent factors associated with antifungal use in the neonatal, pediatric, and adult patient groups. Results For the neonatal, pediatric, and adult patient groups, 54, 44, and 60 hospitals were included, respectively. Total antifungal use was significantly lower in the neonatal patient group (14 days of therapy (DOT)/1000 patient days (PDs) versus 76 in pediatrics and 74 in adults, p
- Published
- 2018